Input Symbol
(pharmaceutics and related company):

Show Other Options

US Clinical Trail Options
Field(s): Type(s): Status(es): Phase(s):
Default Sorting:
US FDA Submission Options
Field(s): Class(s): Type(s):
US Drug Marketing Status Options
Field(s):
EU Drug Marketing Status Options
Field(s):
CA Drug Marketing Status Options
Field(s):
General Options
Historical Years: Display Records Number:
Plot Options & Overlay
Price Chart: Technical Indicators: Clinical Trails: FDA Submissions:
US Marketing: EU Marketing: CA Marketing:
Full Name:Abb Vie Inc. Industry:pharmaceuticals CIK:1551152 Fiscal Year End:12-31 State/Country:ILLINOIS

Check Quant Chart for other overlays (E.g. SEC filings, Insider tradings) to get more accurate projection of price movement

Show Plot Instructions       Expand All

Instructions

US clinical trial status

Size of symbol reflects the phase of clinical trial. E.g. Phase 3 trial has the largest size.
Shape definition
Up-triangle: study first submitted.
Square: study completion(actual/anticipated).
Circle: result first posted.
Color definition
Green: study is ongoing.
Blue: recruitment completed.
Red: study aborted/terminated/withdrawn.
Pink: study in abnormal state.

US FDA submission

Size of symbol reflects the type of submission. E.g. Type 1 drug has the largest size.
: Approved.
: Tentative Approval.

Drug marketing & current status

Circle bubble denotes new drug marketing. Size is determined by drug type and market(i.e. population) size. E.g. Type 1 drug marketed in US has the largest size. Drug marketed in CA has the smallest size due to small population size.
Color definition
Blue circle: drug marketed (EU,CA), FDA submission approved (US).
Cyan circle: drug approved (CA), tentative approval (US), received positive opinion (EU)
Red circle: drug marketed/approved on the corresponding day but was later withdrawn, discontinued, cancelled, or received negative opinion.

Drug marketing status change

Square bubble denotes marketing status change. Size is determined by drug type and market(i.e. population) size.
Color definition
Blue square: change from other status to marketed.
Cyan square: change from other status to tentative status.
Red square: change from other status to abnormal or withdrawn status.

US Clinical Trials

Clinical Trials Summary Statistics

Year Recruiting Enrolling By Invitation Active, Not Recruiting Not Yet Recruiting Completed Terminated Withdrawn
ALL 19 16 4 119 30 6
2024 1 1 3
2023 8 1 1 9 1
2022 5 2 12 2
Year Recruiting Enrolling By Invitation Active, Not Recruiting Not Yet Recruiting Completed Terminated Withdrawn
ALL 2 3 10 4
2024
2023 1 1
2022
Year Recruiting Enrolling By Invitation Active, Not Recruiting Not Yet Recruiting Completed Terminated Withdrawn
ALL 19 1 9 1 124 20 3
2024
2023 7
2022 4 1 1
Year Recruiting Enrolling By Invitation Active, Not Recruiting Not Yet Recruiting Completed Terminated Withdrawn
ALL 4 1 9
2024 1 1
2023 2
2022
Year Recruiting Enrolling By Invitation Active, Not Recruiting Not Yet Recruiting Completed Terminated Withdrawn
ALL 34 7 39 4 166 7 4
2024 2 1
2023 16 2 2 2 1
2022 9 3 1
Year Recruiting Enrolling By Invitation Active, Not Recruiting Not Yet Recruiting Completed Terminated Withdrawn
ALL 3 3 2 22 2 1
2024 1 2
2023 2
2022 2 2
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 19 2 19 4 34 3
2024 1 1 2 1
2023 8 1 7 2 16 2
2022 5 4 9
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 1 7
2024
2023 2
2022
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 16 3 9 39 3
2024 1
2023 1 1 2
2022 2 1 3 2
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 4 1 1 4 2
2024 3 1 1 2
2023 1 2
2022 1 1
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 119 10 124 9 166 22
2024
2023 9 1
2022 12 2
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 30 4 20 7 2
2024
2023 1
2022 2
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 6 3 4 1
2024
2023
2022
Phase Recruiting Enrolling By Invitation Active, Not Recruiting Not Yet Recruiting Completed Terminated Withdrawn
Phase 1 19 16 4 119 30 6
Phase 1|Phase 2 2 3 10 4
Phase 2 19 1 9 1 124 20 3
Phase 2|Phase 3 4 1 9
Phase 3 34 7 39 4 166 7 4
Phase 4 3 3 2 22 2 1
Phase Recruiting Enrolling By Invitation Active, Not Recruiting Not Yet Recruiting Completed Terminated Withdrawn
Phase 1 1 1 3
Phase 1|Phase 2
Phase 2
Phase 2|Phase 3 1 1
Phase 3 2 1
Phase 4 1 2
Phase Recruiting Enrolling By Invitation Active, Not Recruiting Not Yet Recruiting Completed Terminated Withdrawn
Phase 1 8 1 1 9 1
Phase 1|Phase 2 1 1
Phase 2 7
Phase 2|Phase 3 2
Phase 3 16 2 2 2 1
Phase 4 2
Phase Recruiting Enrolling By Invitation Active, Not Recruiting Not Yet Recruiting Completed Terminated Withdrawn
Phase 1 5 2 12 2
Phase 1|Phase 2
Phase 2 4 1 1
Phase 2|Phase 3
Phase 3 9 3 1
Phase 4 2 2

Note: "Year" represents clinical trail start year determined by study first submit date.
Three grouping strategies present the same statistical data from different angles, choose any one you are comfortable with.
at least one study with latest update posted within 7 days.  at least one study with latest update posted within 30 days.  at least one study with latest update posted within 90 days. 

Clinical Trials Records

Sponsor Overall Status Phase Brief Title Disease Condition Intervention Name Study First Submit Date Last Update Post Date Results First Post Date Completion Date Completion Date Type Enrollment Count
AbbVie Not yet recruiting Phase 2|Phase 3 A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants Hypothyroidism Armour Thyroid|Levothyroxine 2024-03-27 2024-04-03 2028-06-03 Anticipated 2800
AbbVie Not yet recruiting Phase 3 Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Crohn's Disease Upadacitinib 2024-03-19 2024-03-27 2034-12-20 Anticipated 110
AbbVie Recruiting Phase 3 A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines Glabellar Lines AGN-151586|Placebo 2024-03-07 2024-04-26 2025-03-22 Anticipated 160
AbbVie Recruiting Phase 3 Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity in Adult Participants With Migraine Migraine Atogepant|Placebo for Atogepant 2024-01-28 2024-03-25 2025-11-30 Anticipated 1300
AbbVie Recruiting Phase 2|Phase 3 Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Non-Small Cell Lung Cancer Livmoniplimab|Budigalimab|Pembrolizumab|Pemetrexed|Cisplatin|Carboplatin 2024-01-24 2024-04-26 2031-10-08 Anticipated 840
AbbVie Recruiting Phase 3 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma Follicular Lymphoma (FL) Epcoritamab|Prednisone|Rituximab|Lenalidomide|Doxorubicin|Vincristine 2023-12-20 2024-04-02 2037-05-19 Anticipated 900
AbbVie Active, not recruiting Phase 3 A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants Forehead Lines BOTOX|Placebo 2023-12-08 2024-04-17 2024-09-18 Anticipated 140
AbbVie Not yet recruiting Phase 3 Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma Multiple Myeloma ABBV-383|Carfilzomib|Pomalidomide|Elotuzumab|Selinexor|Bortezomib 2023-11-28 2023-12-22 2027-12-06 Anticipated 380
AbbVie Recruiting Phase 3 A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants Masseter Muscle Prominence BOTOX|Placebo for BOTOX 2023-11-14 2024-02-20 2026-01-10 Anticipated 250
AbbVie Enrolling by invitation Phase 3 A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo Vitiligo Upadacitinib|Placebo 2023-11-01 2024-03-28 2028-02-05 Anticipated 540
AbbVie Recruiting Phase 2|Phase 3 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) Hepatocellular Carcinoma Livmoniplimab|Budigalimab|Durvalumab|Atezolizumab|Bevacizumab|Tremelimumab 2023-10-26 2024-04-01 2030-09-06 Anticipated 660
AbbVie Recruiting Phase 3 A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab Juvenile Psoriatic Arthritis Adalimumab|Risankizumab 2023-10-20 2024-04-09 2028-10-07 Anticipated 40
AbbVie Not yet recruiting Phase 3 Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein Non-Small Cell Lung Cancer Telisotuzumab Vedotin|Osimertinib|Cisplatin|Carboplatin|Pemetrexed 2023-10-17 2023-10-23 2028-04-11 Anticipated 250
AbbVie Recruiting Phase 3 A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants Masseter Muscle Prominence BOTOX|Placebo 2023-09-29 2024-04-11 2025-11-25 Anticipated 248
AbbVie Recruiting Phase 3 A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. Crohn's Disease Risankizumab SC|Placebo for risankizumab 2023-09-26 2024-04-25 2028-02-23 Anticipated 276
AbbVie Recruiting Phase 2|Phase 3 A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adult Participants for the Treatment of Nasolabial Folds Nasolabial Folds No-Treatment Control|HAC 20L 2023-08-25 2024-01-23 2026-08-19 Anticipated 255
AbbVie Recruiting Phase 3 A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata Alopecia Areata Upadacitinib|Placebo 2023-08-22 2024-04-26 2028-01-22 Anticipated 1500
AbbVie Recruiting Phase 3 A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease Crohn's Disease Risankizumab|Risankizumab 2023-08-10 2024-04-19 2029-04-28 Anticipated 110
AbbVie Recruiting Phase 3 ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars Atrophic Acne Scars ELAPR002f Injectable Gel|Saline Control 2023-08-10 2024-03-26 2025-08-18 Anticipated 156
AbbVie Recruiting Phase 3 A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Hidradenitis Suppurativa Upadacitinib|Placebo 2023-05-26 2024-03-06 2027-08-01 Anticipated 1328
AbbVie Completed Phase 3 A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants Dry Eye Syndrome ABBV-444 2023-05-24 2023-12-12 2023-10-06 Actual 40
AbbVie Recruiting Phase 3 Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine Migraine Atogepant|Placebo for Atogepant 2023-05-08 2023-11-14 2025-05-28 Anticipated 520
AbbVie Recruiting Phase 3 Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus Systemic Lupus Erythematosus Upadacitinib|Placebo 2023-04-25 2024-04-26 2027-10-31 Anticipated 1000
AbbVie Recruiting Phase 3 A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants Facial Volume Deficit HAC 22L 2023-04-06 2023-10-02 2026-09-18 Anticipated 259
AbbVie Recruiting Phase 3 Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis Rheumatoid Arthritis Upadacitinib|Adalimumab|Upadacitinib Matching Placebo|Adalimumab Matching Placebo 2023-04-04 2024-04-26 2026-08-15 Anticipated 480
AbbVie Recruiting Phase 3 Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. Ulcerative Colitis Upadacitinib 2023-03-13 2024-04-19 2033-10-31 Anticipated 110
AbbVie Recruiting Phase 3 Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine Migraine Atogepant|Placebo for Atogepant|Topiramate|Placebo for Topiramate 2023-02-20 2024-04-23 2026-06-29 Anticipated 520
AbbVie Active, not recruiting Phase 3 A Study to Assess Adverse Events and Effectiveness of Injected JUVÉDERM® VOLITE™ Gel Filler for Change in Neck Lines in Adult Chinese Participants Neck Lines JUVÉDERM® VOLITE™|Control 2023-02-14 2023-12-01 2024-12-15 Anticipated 159
AbbVie Recruiting Phase 3 A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine Episodic Migraine Atogepant|Placebo-Matching Atogepant 2023-01-26 2024-04-22 2028-05-04 Anticipated 450
AbbVie Enrolling by invitation Phase 3 Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine Episodic Migraine Atogepant 2023-01-24 2024-02-08 2029-11-16 Anticipated 250
AbbVie Recruiting Phase 3 A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation Functional Constipation (FC)|Chronic Idiopathic Constipation (CIC) Linaclotide|Placebo for Linaclotide 2022-12-02 2024-04-25 2025-11-14 Anticipated 116
AbbVie Recruiting Phase 3 Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. Juvenile Idiopathic Arthritis Upadacitinib|Tocilizumab 2022-11-07 2024-04-26 2029-06-19 Anticipated 90
AbbVie Active, not recruiting Phase 3 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Atopic Dermatitis Upadacitinib|Dupilumab 2022-10-31 2024-04-24 2024-08-08 Anticipated 880
AbbVie Recruiting Phase 3 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Diffuse Large B-Cell Lymphoma Epcoritamab|Cyclophosphamide|Rituximab|Vincristine|Doxorubicin|Prednisone 2022-10-12 2024-04-09 2029-12-30 Anticipated 900
AbbVie Active, not recruiting Phase 3 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the Mouth Perioral Lines JUVÉDERM® VOLITE™|Control 2022-07-08 2023-09-07 2024-10-27 Anticipated 198
AbbVie Recruiting Phase 3 Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD Autism Spectrum Disorder Cariprazine|Placebo 2022-06-28 2024-04-23 2024-11-25 Anticipated 152
AbbVie Recruiting Phase 3 Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma Open-Angle Glaucoma XEN45 (Glaucoma Gel Stent) 2022-06-06 2024-04-15 2025-08-15 Anticipated 65
AbbVie Recruiting Phase 3 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma Follicular Lymphoma (FL) Epcoritamab|Rituximab|Lenalidomide 2022-06-03 2024-04-09 2030-06-16 Anticipated 500
AbbVie Recruiting Phase 3 Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia Schizophrenia Cariprazine|Placebo 2022-05-06 2024-04-03 2034-08-11 Anticipated 250
AbbVie Not yet recruiting Phase 3 A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis Ulcerative Colitis (UC) Mesalamine|Placebo 2022-03-31 2024-03-29 2026-07-19 Anticipated 80
AbbVie Active, not recruiting Phase 3 A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants Neck Lines VOLITE XC|VOLITE XC 2022-03-31 2023-08-30 2024-12-31 Anticipated 159
AbbVie Recruiting Phase 3 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD AMD|nAMD|Wet Age-related Macular Degeneration|wAMD|WetAMD|CNV RGX-314 Dose 1|RGX-314 Dose 2|Aflibercept (EYLEA®) 2022-01-28 2023-08-21 2025-12-01 Anticipated 465
AbbVie Recruiting Phase 3 Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine Chronic Migraine Atogepant 2022-01-19 2024-03-12 2024-12-27 Anticipated 75

Note: Use 'Search' box on top right cornor to narrow down search results. E.g. type in "phase 3" (case insensitive, with double quote) to show Phase 3 trials.
latest update posted within 7 days.  latest update posted within 30 days.  latest update posted within 90 days. 

US FDA Submissions

US FDA Submission Summary Statistics*

Year TYPE 1 TYPE 1/4 TYPE 2 TYPE 2/3 TYPE 3 TYPE 3/4 TYPE 4 TYPE 5 TYPE 6 TYPE 7 TYPE 8 UNKNOWN
ALL 39 3 5 1 47 1 9 16 2 1 1 1
2024
2023
2022 1

Note: "Year" determined by submission status date.
* Original submissions only. Supplementary records not counted.
at least one submission within 7 days.  at least one submission within 30 days.  at least one submission within 90 days. 

US FDA Submission Records

Sponsor Application Type Drug Name Active Ingredient Submission Code Submission Type Submission Status Status Date Application Number
Abbvie Inc BLA Skyrizi Risankizumab Rzaa Type 3 Orig Approval 2022-06-16 761262

Note: Use 'Search' box on top right cornor to narrow down search results. E.g. type in "NDA" (case insensitive) to show records with "NDA" (New Drug Applications) tag.
submission status date within 7 days.  submission status date within 30 days.  submission status date within 90 days. 

US Drug Marketing Status
Category Sponsor Marketing Date Current Marketing Status Drug Name Active Ingredient Submission Status Date Submission Code Submission Status Marketing Status Change Date
Human Non-Bioproduct Abbvie Inc 2022-06-16 Prescription Skyrizi Risankizumab Rzaa 2022-06-16 Type 3 Approval 2023-11-30
Human Non-Bioproduct Abbvie 2019-08-16 Prescription Rinvoq Upadacitinib 2019-08-16 Type 1 Approval 2022-03-29
Human Non-Bioproduct Abbvie 2019-08-16 Prescription Rinvoq Upadacitinib 2019-08-16 Type 1 Approval 2022-02-15
Human Non-Bioproduct Abbvie 2010-06-21 Discontinued Namenda Xr Memantine Hydrochloride 2010-06-21 Type 3 Approval 2023-11-30
Human Non-Bioproduct Abbvie 2009-01-27 Discontinued Gelnique Oxybutynin Chloride 2009-01-27 Type 3 Approval 2023-11-30
Human Non-Bioproduct Abbvie 2008-05-29 Discontinued Asacol Hd Mesalamine 2008-05-29 Type 3 Approval 2023-11-30
Human Non-Bioproduct Abbvie 2004-12-22 Discontinued Enablex Darifenacin Hydrobromide 2004-12-22 Type 1 Approval 2022-01-18
Human Non-Bioproduct Abbvie 2004-12-22 Discontinued Enablex Darifenacin Hydrobromide 2004-12-22 Type 1 Approval 2022-01-18
Human Non-Bioproduct Abbvie 1996-03-01 Discontinued Norvir Ritonavir 1996-03-01 Type 1 Approval 2023-11-30
Human Non-Bioproduct Abbvie 1995-09-29 Discontinued Androderm Testosterone 1995-09-29 Type 3 Approval 2023-11-30
Human Non-Bioproduct Abbvie 1995-09-29 Discontinued Androderm Testosterone 1995-09-29 Type 3 Approval 2023-11-30
Human Non-Bioproduct Abbvie Endocrine Inc 1993-04-16 Prescription Lupron Depot Ped Kit Leuprolide Acetate 1993-04-16 Type 5 Approval 2023-11-30
Human Non-Bioproduct Abbvie 1980-06-09 Discontinued K Tab Potassium Chloride 1980-06-09 Type 3 Approval 2023-11-30
Human Non-Bioproduct Abbvie 1980-06-09 Discontinued K Tab Potassium Chloride 1980-06-09 Type 3 Approval 2022-03-15
Human Non-Bioproduct Abbvie 1980-06-09 Discontinued K Tab Potassium Chloride 1980-06-09 Type 3 Approval 2023-11-30

Note: This table contains human and animal drugs regulated by US FDA, and biological products regulated by CBER (Center for Biologics Evaluation and Research).
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "discontinued" (case insensitive) to show discontinued drug products.
For human non-bioproduct, marketing date was set to submission approval date.
Possible marketing statuses: Marketed, Prescription, Over-the-counter, Discontinued, None (Tentative Approval).
any of (marketing/submission/status change) within 7 days.  any of (marketing/submission/status change) within 30 days.  any of (marketing/submission/status change) within 90 days. 

EU Drug Marketing Status
Category Sponsor Authorization Date Current Marketing Status Latest Status Update Drug Name Active Ingredient Withdraw Date Opinion Date Summary of Opinion
Human Abb Vie Deutschland Gmb H & Co. Kg 2023-09-22 Authorised 2023-10-05 Tepkinly Epcoritamab
Human Abb Vie Deutschland Gmb H & Co. Kg 2023-08-11 Authorised 2023-08-25 Aquipta Atogepant

Note: This table contains human and animal drugs regulated by EMA (European Medicines Agency), and summary of opinion published by EMA based on the CHMP's or CVMP's positive or negative recommendation.
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "withdrawn" (case insensitive) to show drugs withdrawn.
Possible marketing statuses: Authorised, Refused, Withdrawn, Summary of Opinion.
Summary of Opinion: published by European Medicines Agency (EMA) based on the CHMP's or CVMP's positive or negative recommendation. Further marketing authorization is partially based on this opinion.
any of (authorization/withdrawn/opinion/status change) date within 7 days.  any of (authorization/withdrawn/opinion/status change) date within 30 days.  any of (authorization/withdrawn/opinion/status change) date within 90 days. 

CA Drug Marketing Status
Category Sponsor Authorization Date Current Marketing Status Status Date Drug Name Active Ingredient
Human Abbvie Corporation 2015-04-10 Marketed 2024-03-28 Total Defense + Repair Broad Spectrum Spf 34 Sunscreen Zinc Oxide (8%)|Octinoxate (7.5%)|Octisalate (3%)
Human Abbvie Corporation 2015-04-10 Marketed 2024-03-27 Total Defense + Repair Broad Spectrum Spf 34 Sunscreen Tinted Zinc Oxide (8%)|Octinoxate (7.5%)|Titanium Dioxide (3.5%)|Octisalate (3%)
Human Abbvie Corporation 2023-05-03 Marketed 2024-02-05 Vyalev Foslevodopa (240 Mg)|Foscarbidopa (12 Mg)
Human Abbvie Corporation 2024-01-25 Marketed 2024-01-25 Refresh Optive Advanced Carboxymethylcellulose Sodium (0.5%)|Glycerine (1%)|Polysorbate 80 (0.5%)
Human Abbvie Corporation 2024-01-22 Marketed 2024-01-22 Refresh Liquigel Carboxymethylcellulose Sodium (1%)
Human Abbvie Corporation 2024-01-22 Marketed 2024-01-22 Refresh Optive Fusion Carboxymethylcellulose Sodium (0.5%)|Glycerine (0.9%)
Human Abbvie Corporation 2023-10-13 Marketed 2023-12-18 Epkinly Epcoritamab (5 Mg)
Human Abbvie Corporation 2023-10-13 Marketed 2023-12-18 Epkinly Epcoritamab (60 Mg)
Human Abbvie Corporation 2022-09-09 Marketed 2023-11-13 Botox Onabotulinumtoxina (100 Unit)
Human Abbvie Corporation 2022-10-03 Marketed 2023-10-11 Botox Onabotulinumtoxina (200 Unit)
Human Abbvie Corporation 2017-05-03 Marketed 2023-10-10 Refresh Optive Gel Drops Carboxymethylcellulose Sodium (1%)|Glycerine (0.9%)
Human Abbvie Corporation 2023-10-10 Marketed 2023-10-10 Refresh Contacts Carboxymethylcellulose Sodium (0.5%)
Human Abbvie Corporation 2023-09-11 Marketed 2023-09-11 Refresh Optive Advanced Sensitive Carboxymethylcellulose Sodium (0.5%)|Glycerine (1%)|Polysorbate 80 (0.5%)
Human Abbvie Corporation 2023-07-21 Marketed 2023-09-07 Rinvoq Upadacitinib (45 Mg)
Human Abbvie Corporation 2009-04-15 Marketed 2023-08-04 Lumigan Rc Bimatoprost (0.01%)
Human Abbvie Corporation 2015-07-16 Cancelled Post Market 2023-07-20 Viibryd Vilazodone Hydrochloride (10 Mg)|Vilazodone Hydrochloride (20 Mg)
Human Abbvie Corporation 2018-06-01 Marketed 2023-07-19 Restasis Multidose Cyclosporine (0.05%)
Human Abbvie Corporation 1999-02-26 Marketed 2023-06-23 Refresh Tears Carboxymethylcellulose Sodium (0.5%)
Human Abbvie Corporation 2022-10-03 Marketed 2023-06-20 Botox Onabotulinumtoxina (50 Unit)
Human Abbvie Corporation 2023-06-20 Marketed 2023-06-20 Tears Plus Polyvinyl Alcohol (1.4%)
Human Abbvie Corporation 2023-06-19 Marketed 2023-06-19 Refresh Polyvinyl Alcohol (1.4%)
Human Abbvie Corporation 2004-11-12 Marketed 2023-06-16 Refresh Celluvisc Carboxymethylcellulose Sodium (1%)
Human Abbvie Corporation 2023-06-15 Marketed 2023-06-15 Refresh Plus Carboxymethylcellulose Sodium (0.5%)
Human Abbvie Corporation 2022-11-10 Marketed 2023-05-11 Ubrelvy Ubrogepant (50 Mg)
Human Abbvie Corporation 2022-11-10 Marketed 2023-04-04 Ubrelvy Ubrogepant (100 Mg)
Human Abbvie Corporation 2022-12-22 Marketed 2023-03-24 Qulipta Atogepant (10 Mg)
Human Abbvie Corporation 2023-03-17 Marketed 2023-03-17 Albalon Naphazoline Hydrochloride (0.1%)
Human Abbvie Corporation 2022-10-19 Marketed 2023-03-14 Skyrizi Risankizumab (360 Mg)
Human Abbvie Corporation 2022-12-22 Marketed 2023-03-01 Qulipta Atogepant (60 Mg)
Human Abbvie Corporation 2022-12-22 Marketed 2023-02-23 Qulipta Atogepant (30 Mg)
Human Abbvie Corporation 2004-11-29 Marketed 2023-01-13 Refresh Lacri Lube Mineral Oil (42.5%)|White Petrolatum (57.3%)
Human Abbvie Corporation 2023-01-13 Marketed 2023-01-13 Refresh Eye Allergy Relief Antazoline Phosphate (0.51%)|Naphazoline Hydrochloride (0.051%)
Human Abbvie Corporation 2022-10-19 Marketed 2022-12-01 Skyrizi Risankizumab (60 Mg)
Human Abbvie Corporation 2015-07-16 Marketed 2022-11-21 Viibryd Vilazodone Hydrochloride (10 Mg)
Human Abbvie Corporation 2015-07-16 Marketed 2022-11-21 Viibryd Vilazodone Hydrochloride (20 Mg)
Human Abbvie Corporation 2015-07-16 Marketed 2022-11-21 Viibryd Vilazodone Hydrochloride (40 Mg)
Human Abbvie Corporation 1994-07-15 Marketed 2022-11-16 Salofalk Mesalazine (4 G)
Human Abbvie Corporation 1994-07-15 Marketed 2022-11-16 Salofalk Mesalazine (2 G)
Human Abbvie Corporation 2011-06-15 Marketed 2022-11-16 Acuvail Ketorolac Tromethamine (0.45%)
Human Abbvie Corporation 1994-07-15 Marketed 2022-11-14 Salofalk Mesalazine (500 Mg)
Human Abbvie Corporation 2000-05-03 Marketed 2022-11-14 Salofalk Mesalazine (1000 Mg)
Human Abbvie Corporation 2022-11-08 Marketed 2022-11-08 Acular Ketorolac Tromethamine (0.5%)
Human Abbvie Corporation 2004-01-12 Marketed 2022-11-08 Acular Ls Ketorolac Tromethamine (0.4%)
Human Abbvie Corporation 2012-12-21 Marketed 2022-11-08 Bystolic Nebivolol (Nebivolol Hydrochloride) (2.5 Mg)
Human Abbvie Corporation 2012-12-21 Marketed 2022-11-08 Bystolic Nebivolol (Nebivolol Hydrochloride) (5 Mg)
Human Abbvie Corporation 2012-12-21 Marketed 2022-11-08 Bystolic Nebivolol (Nebivolol Hydrochloride) (10 Mg)
Human Abbvie Corporation 2012-12-21 Marketed 2022-11-08 Bystolic Nebivolol (Nebivolol Hydrochloride) (20 Mg)
Human Abbvie Corporation 1994-07-15 Marketed 2022-11-07 Salofalk Mesalazine (500 Mg)
Human Abbvie Corporation 2002-12-09 Marketed 2022-11-04 Actonel Risedronate Sodium (Risedronate Sodium Hemipentahydrate) (35 Mg)
Human Abbvie Corporation 2008-09-24 Marketed 2022-11-04 Actonel Risedronate Sodium (Risedronate Sodium Hemipentahydrate) (150 Mg)
Human Abbvie Corporation 2011-07-27 Marketed 2022-11-04 Actonel Dr Risedronate Sodium (Risedronate Sodium Hemipentahydrate) (35 Mg)

Note: This table contains human, animal drugs, radiopharmaceutical and disinfectant regulated by CFIA(Canadian Food Inspection Agency) and Health Canada.
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "marketed" (case insensitive) to show drugs marketed.
Possible marketing statuses: Marketed, Approved, Dormant, Cancelled Pre Market, Cancelled Post Market, Cancelled (Safety Issue), Cancelled (Unreturned Annual).
any of (authorization/status change) date within 7 days.  any of (authorization/status change) date within 30 days.  any of (authorization/status change) date within 90 days.